Globeflex Capital L P Affimed N.V. Transaction History

Globeflex Capital L P

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$5.37 - $7.07 $2,217 - $2,919	-413 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.54 - $7.51 $2,288 - $3,101	413 New	413 $3,000
Q1 2021 May 14, 2021	SELL	$5.12 - $8.48 $1.87 Million - $3.1 Million	-365,352 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$3.16 - $7.03 $722,764 - $1.61 Million	-228,723 Reduced 38.5%	365,352 $2.13 Million
Q3 2020 Nov 13, 2020	SELL	$3.26 - $4.73 $12,348 - $17,917	-3,788 Reduced 0.63%	594,075 $2.01 Million
Q2 2020 Aug 12, 2020	BUY	$1.58 - $4.63 $944,623 - $2.77 Million	597,863 New	597,863 $2.76 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Globeflex Capital L P, based on Form 13F filings with the SEC.

Stay updated on Globeflex Capital L P with notifications on news.